Company Overview

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics for pulmonary hypertension and other serious diseases with significant unmet medical need. The company operates within the biotechnology and life sciences industries, with its primary strategic emphasis centered on pulmonary arterial hypertension (PAH). Gossamer Bio’s lead value driver is seralutinib, an inhaled platelet-derived growth factor receptor (PDGFR), colony stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor designed to address the underlying pathology of PAH. The company has historically pursued immunology, oncology, and pulmonary programs, though its current operational focus is concentrated on pulmonary vascular disease.

Gossamer Bio was founded in 2018 by a group of biotechnology executives associated with the “asset-centric” development model previously used at Receptos and other biotechnology ventures. The company rapidly expanded through in-licensing and acquisition of clinical-stage assets before refining its portfolio around pulmonary hypertension. Its positioning is differentiated by its inhaled therapeutic approach, intended to maximize pulmonary exposure while limiting systemic toxicity, and by its concentration on disease-modifying mechanisms rather than symptom management alone.

Business Operations

Gossamer Bio primarily operates through a single biotechnology development platform focused on advancing its therapeutic pipeline through clinical development, regulatory engagement, and potential commercialization partnerships. The company does not currently generate material commercial product revenue and instead finances operations through equity offerings, strategic financing transactions, and collaborations. Its principal development asset, seralutinib, is being evaluated for PAH and related pulmonary vascular conditions through global clinical trials, including Phase 3 development activities announced following earlier Phase 2 studies.

The company’s operations are headquartered in the United States, with clinical trial activities extending internationally through research organizations, trial sites, and regulatory coordination in multiple jurisdictions. Gossamer Bio relies on outsourced manufacturing and development infrastructure common among clinical-stage biotechnology firms while maintaining internal expertise in translational medicine, regulatory affairs, and clinical development. Historically, the company controlled several development-stage subsidiaries and asset programs acquired through licensing transactions, though portfolio rationalization has narrowed its active operational concentration around pulmonary therapeutics.

Strategic Position & Investments

Gossamer Bio’s strategic direction is centered on establishing leadership in pulmonary hypertension through advancement of seralutinib and related pulmonary vascular disease programs. The company has prioritized late-stage clinical development and regulatory preparation intended to position seralutinib as a potentially disease-modifying therapy in PAH. Strategic initiatives have included expanding clinical evidence generation, strengthening manufacturing readiness, and evaluating broader pulmonary hypertension indications beyond Group 1 PAH.

The company has historically expanded through licensing and acquisition transactions involving external biotechnology innovators and academic-originated assets. Earlier pipeline assets included programs in immunology and oncology, though management has concentrated capital allocation toward pulmonary disease opportunities considered higher priority. Gossamer Bio has also engaged with institutional healthcare investors and strategic financing partners to support development activities. Public filings and investor communications indicate continued emphasis on precision pulmonary therapeutics, inhaled drug delivery technologies, and biomarker-driven clinical strategies.

Geographic Footprint

Gossamer Bio is headquartered in San Diego, California, a major biotechnology hub in the United States. While the company’s core corporate operations are U.S.-based, its clinical development activities involve multinational trial sites and collaborations across North America, Europe, and other international markets relevant to pulmonary hypertension research and regulatory development.

The company’s operational footprint is primarily tied to clinical trial execution, manufacturing partnerships, and regulatory engagement rather than commercial infrastructure. Gossamer Bio’s international presence is therefore driven by development-stage activities, including patient enrollment, investigator networks, and contract research partnerships in multiple global regions where pulmonary vascular disease expertise and specialty treatment centers are established.

Leadership & Governance

Gossamer Bio was co-founded by executives with prior experience building and commercializing biotechnology companies, particularly within immunology and specialty therapeutics. Leadership has consistently emphasized disciplined capital allocation, targeted asset acquisition, and development of differentiated therapies addressing significant unmet medical needs. The company’s governance structure follows standard U.S. public biotechnology company practices, with oversight from a board of directors composed of biotechnology, clinical, and financial industry leaders.

Key executives include:

• Faheem Hasnain – Chairman of the Board
• Joshua H. Fink – Chief Executive Officer
• Diana M. Brainard, M.D. – Chief Medical Officer
• Chris Cargill – Chief Financial Officer
• Steve Martin – President and Chief Operating Officer

Management communications and public filings have emphasized a strategy focused on advancing pulmonary hypertension therapeutics through rigorous clinical development, operational efficiency, and long-term value creation tied to differentiated science and targeted specialty markets.